Weekly Watched Assets — 2026-09-25
7 high-conviction US stocks identified from monthly sentiment analysis.
INIO — INNIO
1W -9.3% | 1M -13.4% | 3M -49.0% | YTD -43.6%
"critical mispricing opportunity"
Thesis: INIO presents a high-conviction contrarian opportunity with extreme mispricing amid strong fundamentals, including backlog and order outperformance, creating a clear path to structural re-rating. The stock's severe underperformance amplifies the asymmetric risk/reward profile. Conviction: 98% (high)
ELMT — The Elmet Group
1W -10.2% | 1M +11.2% | 3M +4.1% | YTD +10.2%
"game-changing event—transforming ELMT from a junior explorer into a cornerstone of U.S. industrial resilience and national security infrastructure"
Thesis: Backed by a $2 billion DLA contract and direct U.S. government endorsement, ELMT is de-risking its growth trajectory with a transformational shift from exploration to contract-driven revenue, setting up a structural re-rating by H2 2028. Institutional adoption remains low, enhancing upside potential. Conviction: 96% (high)
EW — Edwards Lifesciences Corporation
1W -2.9% | 1M -5.7% | 3M -5.6% | YTD +0.5%
"transformative policy change"
Thesis: A transformative CMS policy change and upcoming FDA approval for PASCAL create a time-sensitive catalyst for a structural re-rating in EW, despite current market skepticism. The profound disconnect between durable fundamentals and valuation supports a multi-bagger trajectory. Conviction: 96% (high)
GD — General Dynamics Corporation
1W -5.5% | 1M -10.7% | 3M -2.6% | YTD -0.8%
"The most significant anomaly in the defense sector is GD’s underperformance despite exceptional fundamentals"
Thesis: GD exhibits exceptional fundamentals amid unexplained underperformance, creating a deep value inflection with asymmetric risk/reward. Anticipated transformative DoD contracts serve as a near-term catalyst for aggressive accumulation and re-rating. Conviction: 96% (high)
ISRG — Intuitive Surgical, Inc.
1W +4.2% | 1M +7.4% | 3M -1.3% | YTD -28.9%
"indicating a profound disconnect between fundamentals and market sentiment, with valuation metrics suggesting a potential mispricing of one of the most durable businesses in healthcare"
Thesis: ISRG shows a profound disconnect between market sentiment and fundamentals, underscored by landmark regulatory milestones and peer-reviewed clinical validation driving adoption. Despite YTD weakness, it offers a durable business model poised for re-rating. Conviction: 95% (high)
VMC — Vulcan Materials Company
1W -1.1% | 1M -11.8% | 3M -22.2% | YTD -16.9%
"Bridgewater’s decisive new stake in VMC amid a 14% YTD decline and D+ Momentum Grade is a critical contrarian signal—highlighting that elite investors see real value in VMC’s entrenched market position and infrastructure tailwinds, even as the broader market remains skeptical."
Thesis: Bridgewater's new stake in VMC signals elite investor conviction in its value amid Sunbelt infrastructure tailwinds and delayed spendup, despite negative momentum. The significant margin of safety supports a contrarian recovery play. Conviction: 95% (high)
TRMB — Trimble Inc.
1W +0.6% | 1M -2.9% | 3M +13.8% | YTD -26.4%
"a structural re-rating"
Thesis: TRMB is positioned for a structural re-rating if it executes on its software and AI transformation, with Goldman Sachs-led divestiture acting as a catalyst. However, lingering skepticism about scale execution adds uncertainty relative to peers. Conviction: 95% (high)